Related Experiment Video
Updated: Feb 26, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.8K
Immunohistochemistry in Acute Myeloid Leukemia
1Pathology Department, Cleveland Clinic Main Campus, Mail Code L25, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. cruisem@ccf.org.
Methods in Molecular Biology (Clifton, N.J.)
|July 24, 2017
Summary
Immunohistochemical studies are crucial for diagnosing acute myeloid leukemia (AML) and determining prognosis. Evaluating bone marrow biopsies with these techniques aids in accurate classification according to WHO guidelines.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- The World Health Organization (WHO) classification integrates genetic, molecular, morphologic, and immunophenotypic features for classifying hematopoietic and lymphoid tumors.
- Acute myeloid leukemia (AML) diagnosis requires ≥20% blasts, with exceptions for specific cytogenetic abnormalities or erythroleukemia.
- Diagnostic workup involves morphologic, cytochemical, and immunophenotypic analyses of peripheral blood and bone marrow.
Purpose of the Study:
- To highlight the critical role of immunohistochemical studies in the classification of acute myeloid leukemia (AML).
- To emphasize the importance of bone marrow biopsy evaluation for diagnostic and prognostic assessments in AML.
Main Methods:
- Morphologic, cytochemical, and immunophenotypic evaluation of peripheral blood and bone marrow aspirates.
- Histopathological examination of bone marrow trephine biopsies.
- Application of immunohistochemical studies on bone marrow biopsy specimens.
Main Results:
- Bone marrow biopsies provide essential material for immunohistochemical analysis.
- Immunohistochemistry aids in differentiating AML subtypes and assessing prognostic factors.
- Accurate classification relies on a comprehensive approach including biopsy evaluation.
Conclusions:
- Immunohistochemical studies are indispensable for the accurate classification and prognostication of AML.
- The WHO classification framework underscores the necessity of integrating diverse diagnostic modalities, including immunohistochemistry.
- Adequate bone marrow biopsy evaluation is paramount for effective AML diagnosis and management.
